BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,356 | +169.0% | 191,527 | +167.8% | 0.12% | +132.0% |
| Q2 2023 | $504 | -60.7% | 71,532 | -53.5% | 0.05% | -60.6% |
| Q1 2023 | $1,282 | -99.5% | 153,718 | +703.9% | 0.13% | +296.9% |
| Q3 2022 | $241,000 | -59.2% | 19,121 | -53.5% | 0.03% | -46.7% |
| Q3 2021 | $591,000 | -27.6% | 41,116 | -48.7% | 0.06% | -55.6% |
| Q1 2021 | $816,000 | +946.2% | 80,197 | +663.8% | 0.14% | +938.5% |
| Q4 2020 | $78,000 | -58.7% | 10,500 | -73.5% | 0.01% | -87.6% |
| Q2 2020 | $189,000 | -31.8% | 39,599 | -71.4% | 0.10% | +52.2% |
| Q1 2020 | $277,000 | -15.8% | 138,664 | +243.4% | 0.07% | +109.1% |
| Q1 2019 | $329,000 | +376.8% | 40,383 | +208.6% | 0.03% | +560.0% |
| Q3 2017 | $69,000 | -84.0% | 13,086 | -63.0% | 0.01% | -83.3% |
| Q4 2014 | $430,000 | -19.6% | 35,350 | -35.3% | 0.03% | +7.1% |
| Q3 2014 | $535,000 | – | 54,674 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |